Table 1.
Study cohort.
| Total subjects | n = 303 |
|---|---|
| Race, n (%) | |
| Asian | 7 (2.36) |
| Black or African American | 5 (1.68) |
| Multiple | 4 (1.35) |
| Other | 10 (3.37) |
| Prefer not to answer | 3 (1.01) |
| White | 268 (90.24) |
| Hispanic, n (%) | 15 (5.05) |
| Gender, female, n (%) | 166 (55.89) |
| Vaccine type, n (%) | |
| BNT162 (Pfizer/BioNtech) | 160 (52.81) |
| JNJ-78436725 (Johnson & Johnson) | 15 (4.95) |
| mRNA-1273 (Moderna/NIH) | 128 (42.24) |
| Prior COVID-19 history, n (%) | 15 (5.08) |
| Treatments, n (%) | |
| No immune suppression | 48 (16.22) |
| Anti-TNF | 104 (35.14) |
| Other biologics (anit-IL23, anti-integrin) | 126 (42.57) |
| Immunomodulators | 18 (6.08) |
| Age group, n (%) | |
| ≤30 | 44(14.52) |
| 30–40 | 83(27.39) |
| 40–50 | 71(23.43) |
| 50–60 | 45(14.85) |
| >60 | 60(19.8) |
Abbreviations: COVID-19, coronavirus disease 2019; IL, interleukin; JNJ, Johnson & Johnson; mRNA, messenger RNA; TNF, tumor necrosis factor.